Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4179.50 +0.2% SILVER 57.24 +0.1% COPPER 6.57 +0.2% OIL 98.94 +1.0% PALLADIUM 1116.00 −1.1% MON 0.385 −6.1% OMI 0.250 +0.0% BUFF 0.800 +2.6% FEO 0.650 +0.0% LIB 0.700 −2.8% NPR 0.620 +0.0% QZM 0.380 +0.0% BVA 0.770 +1.3% ONAU 0.530 +1.9% FMR 0.225 +0.0% GSVR 0.347 +2.2% PHNM 0.345 +1.5% SLG 5.55 −2.8% CASA 0.060 +0.0% DRY 0.220 +2.3% SOMA 0.570 +1.8% GOLD 4179.50 +0.2% SILVER 57.24 +0.1% COPPER 6.57 +0.2% OIL 98.94 +1.0% PALLADIUM 1116.00 −1.1% MON 0.385 −6.1% OMI 0.250 +0.0% BUFF 0.800 +2.6% FEO 0.650 +0.0% LIB 0.700 −2.8% NPR 0.620 +0.0% QZM 0.380 +0.0% BVA 0.770 +1.3% ONAU 0.530 +1.9% FMR 0.225 +0.0% GSVR 0.347 +2.2% PHNM 0.345 +1.5% SLG 5.55 −2.8% CASA 0.060 +0.0% DRY 0.220 +2.3% SOMA 0.570 +1.8%
Earnings

Vext Reports Q3 2025 Financial Results; Revenue Up 41% Year-over-Year and Operating Cash Flow Year-To-Date Reaches $8.5 Million

By The Northwire Desk — AI Analysis Nov 20, 2025 · 06:31 VEXT · 0.255 Vext Science Inc.
VEXT · Price

Executive Summary

  • Vext Science reported Q3 2025 revenue of $12.7 M, up 41% YoY, and generated $8.5 M of operating cash flow YTD.
  • EBITDA was $2.3 M; Adjusted EBITDA $2.1 M (margin 16.7%). Net cash provided by operations turned positive at $1.3 M.
  • Ohio retail footprint expanded to five dispensaries with regulatory approval for three additional locations, positioning the company to hit the state cap of eight dispensaries in 2026.

Key Details

  • Revenue: $12,670 k (Q3 2025) vs. $8,987 k (Q3 2024), +41% YoY.
  • EBITDA: $2,315 k (Q3 2025) vs. $1,926 k (Q3 2024).
  • Adjusted EBITDA: $2,112 k (Q3 2025); Adjusted EBITDA margin 16.7% (down from 32% in Q3 2024).
  • Net cash provided by operating activities: $1,259 k (Q3 2025) vs. $(243) k (Q3 2024).
  • Cash Flow Margin: 9.9% for Q3 2025 (up from –2.7% in Q3 2024).
  • Operating cash flow YTD: $8.5 M, compared to a negative $(0.7) M in Q3 2024 YTD.
  • Ohio expansion: Five consolidated dispensary locations; regulatory approval received on Sep 17 2025 to acquire Herbal Wellness Center (Portsmouth); closing completed Oct 1 2025. Additional three dual‑use dispensaries approved, targeting eight total by 2026.
  • Arizona performance: Continued outperformance of state averages on a per‑store basis despite broader market decline.
  • Management outlook: CEO Eric Offenberger expects continued operational momentum, Q4 cash flow improvement, and construction/licensing progress on three new Ohio locations for 2026.
  • Conference call: Hosted Nov 20 2025 at 08:00 a.m. ET; replay available until Dec 4 2025.

Notable Quotes

“Vext delivered another solid quarter… revenue of $12.7 million, up 41% year‑over‑year, and year‑to‑date operating cash flow of $8.5 million,” – Eric Offenberger, CEO
“We are well placed to leverage our vertically‑integrated platform and growing retail footprint to drive sustainable, profitable growth…” – Eric Offenberger, CEO

Read the original news release →

More from Vext Science Inc.

Jun 01, 2026 · 18:15

Vext Science Opens Sixth Ohio Dispensary, Steady Execution on Retail Build-Out Amidst Arizona Pivot

Production / Operations May 21, 2026 · 06:31

Vext Scales Ohio Operations While Tax Liabilities Loom Over Cash Position

Earnings Apr 29, 2026 · 06:31

Vext Cash Flow Turnaround Meets Tax Reality Check

Earnings Mar 30, 2026 · 17:17

Vext to discontinue operations at Arizona facility

M&A / Property Mar 30, 2026 · 07:31

Vext Pivots from Arizona to Ohio, Trading Fixed Costs for Debt Paydown and Expansion

Production / Operations Mar 03, 2026 · 18:35

Vext receives licence for seventh dispensary in Ohio

Production / Operations